Fig. 1
Genomic profiling of 12 HGSOC PDX. a IHC staining of PAX8, WT1, and p53 of passage one (T1) PDX tumors. Loss of p53 expression was observed for PDX #54 with a frameshift TP53 mutation (p.G199fs*8), #11 with a nonsense TP53 mutation (p.E198*), and #80 with a splice site TP53 mutation (IVS6-1G>T). b Select genomic events detected by the Foundation Medicine T5a test, BROCA assay, and BRCA1 promoter methylation testing. The Foundation Medicine T5a test was performed on PDX samples, except for case #48, where it was performed on patient HGSOC material. T5a test results and BROCA v4 assay results for PDX #11, #13, #27, #29, #56, and #62 were previously published34; BROCA v6 was performed for all other PDX34. c RNA-seq gene expression for genes with detected mutations or copy number changes. RNA-seq was performed on baseline patient HGSOC material samples. RNA-seq was also performed on PDX #169 and #201 samples, to verify expression levels observed in the matched HGSOC with suboptimal sample quality due to either low neoplastic cellularity or poor RNA quality (#80 inadequate quality); rep—RNA-seq library replicate
